Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
83.00
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astrazeneca Plc ADR
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
47
48
Next >
Adagio shares soar on antibody potential against new COVID variant omicron
November 29, 2021
Stifel analyst Stephen Willey believes vaccines alone are unlikely to sufficiently address the COVID-19 pandemic.
Via
Talk Markets
Exposures
COVID-19
3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries
November 29, 2021
The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a h...
Via
Benzinga
Exposures
COVID-19
Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail?
November 29, 2021
Smaller companies are working on next-generation approaches to Covid treatment.
Via
Investor's Business Daily
These Biotech Companies Are Attempting to Use Improved Antibody Technology in the Fight To Eradicate COVID-19
November 29, 2021
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
AstraZeneca: Expected To Move Upwards
November 12, 2021
Today’s instrument is the Astrazeneca Plc. stock traded in the LSE exchange under the ticker AZN.
Via
Talk Markets
Got $5,000? These 2 Stocks Could Be Bargain Buys in 2022
November 27, 2021
Both of these businesses could be in much better shape a year from now.
Via
The Motley Fool
Pfizer's COVID-19 Franchise Could Push Revenue Past $100B In 2022: Analyst
November 23, 2021
Pfizer, Inc. (NYSE:PFE) found huge success with its COVID-19 ...
Via
Benzinga
Exposures
COVID-19
AstraZeneca Decides It's OK to Make Money From the Pandemic
November 23, 2021
Lackluster third-quarter results may have contributed to the decision to stop selling its COVID-19 vaccine at no profit.
Via
The Motley Fool
Exposures
COVID-19
EU Says Decision On J&J COVID-19 Booster Shot Expected 'Within Weeks'
November 22, 2021
The European Medicines Agency (EMA) said it was evaluating data on booster doses of the COVID-19 vaccine by Johnson & Johnson (NYSE: JNJ). The CHMP will recommend...
Via
Benzinga
Exposures
COVID-19
Friday Markets Coverage
November 19, 2021
Today markets are suffering alongside Austria which locked down against Covid-19 again.
Via
Talk Markets
Exposures
COVID-19
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
November 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia...
Via
Benzinga
AstraZeneca's COVID-19 Antibody Shows 83% Protection Over Six Months
November 18, 2021
AstraZeneca Plc (NASDAQ: AZN) has shared new data from two Phase 3 trials of AZD7442, its long-acting antibody (LAAB) combination, in COVID-19 patients. In an...
Via
Benzinga
Exposures
COVID-19
Tuesday Market Overview
November 16, 2021
While gold gained modestly again today, cryptocurrencies fell hard.
Via
Talk Markets
Monday Market Coverage
November 15, 2021
Gold is up today on inflation fears.
Via
Talk Markets
AstraZeneca, Moderna Shares Early Cut Data For mRNA Candidate In Heart Failure
November 15, 2021
Moderna Inc (NASDAQ: MRNA) announced data from the AstraZeneca Plc (NASDAQ: AZN)-led Phase 2 (EPICCURE) study evaluating AZD8601 in patients undergoing...
Via
Benzinga
PhaseBio's Shares Slide As Antiplatelet Candidate Shows Higher Rates Of Side Effect
November 15, 2021
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of...
Via
Benzinga
Consumer Sentiment Hit a Decade Low Due to Rising Inflation
November 15, 2021
Stock index futures are pointing to a higher open as President Joe Biden is expected to sign the infrastructure bill. Additionally, President Biden is scheduled to meet with...
Via
Benzinga
Moderna Posts Interim Data From mRNA Triplet Program In Solid Tumors
November 15, 2021
Moderna Inc (NASDAQ: MRNA) announced interim data from Phase 1 study of mRNA-2752 (Triplet) in patients with accessible solid tumors and lymphomas. The data...
Via
Benzinga
Mid-Afternoon Market Update: Dow Surges 150 Points; Team Shares Drop
November 12, 2021
Toward the end of trading Friday, the Dow traded up 0.42% to 36,071.48 while the NASDAQ rose 0.84% to 15,835.89. The S&P also rose, gaining 0.61% to 4,677.60. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why AstraZeneca Stock Is Sinking Today
November 12, 2021
The drugmaker announced disappointing third-quarter earnings results.
Via
The Motley Fool
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
November 12, 2021
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products.
Via
Talk Markets
Mid-Day Market Update: Everspin Jumps After Q3 Results; Acutus Medical Shares Plummet
November 12, 2021
Midway through trading Friday, the Dow traded up 0.31% to 36,031.95 while the NASDAQ rose 0.54% to 15,788.64. The S&P also rose, gaining 0.43% to 4,669.15. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Mid-Morning Market Update: Markets Rise; AstraZeneca's COVID-19 Vaccine Turns Profitable In Third Quarter
November 12, 2021
Following the market opening Friday, the Dow traded up 0.25% to 36,012.29 while the NASDAQ rose 0.24% to 15,741.23. The S&P also rose, gaining 0.14% to 4,655.99. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
COVID-19
US Equities
Recap: AstraZeneca Q3 Earnings
November 12, 2021
AstraZeneca (NASDAQ:AZN) reported its Q3 earnings results on Friday, November 12, 2021 at 08:00 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
November 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...
Via
Benzinga
AstraZeneca's COVID-19 Vaccine Turns Profitable In Q3; Reaffirms FY21 Guidance
November 12, 2021
AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine made a small contribution to earnings in Q3. It expects the shot to move to "modest profitability" on new...
Via
Benzinga
Exposures
COVID-19
A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Consumer Sentiment Report
November 12, 2021
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after closing mixed in the prior session. Investors are awaiting earnings results from...
Via
Benzinga
5 Stocks To Watch For November 12, 2021
November 12, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects Spectrum Brands Holdings, Inc. (NYSE: SPB) to report quarterly earnings at $0.65 per share on...
Via
Benzinga
This Company's Innovative Targeted Radiation Therapy Could Offer Potential Hope for Cancer Patients
November 11, 2021
Photo by National Cancer Institute on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a...
Via
Benzinga
Earnings Scheduled For November 12, 2021
November 12, 2021
Companies Reporting Before The Bell • Zevia (NYSE:ZVIA) is estimated to report quarterly loss at $0.43 per share on revenue of $34.40 million. • Natura &Co...
Via
Benzinga
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.